^
Association details:
| Biomarker: | GPRC5D overexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Talvey (talquetamab-tgvs) (CD3 agonist, GPRC5D inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
Published date:
04/23/2021
Excerpt:
The most sensitive cell lines, UM9 and MM.1S, had highest GPRC5D expression. Across BM samples, the efficacy of talquetamab was superior in patients with higher than median cell surface expression levels of GPRC5D, when compared with patients with lower expression (P < .0001)...higher efficacy of talquetamab against MM cells with high GPRC5D expression.
DOI:
https://doi.org/10.1182/bloodadvances.2020003805
